PROVIDENCE-STRATEGIC
11.9.2020 10:01:09 CEST | Business Wire | Press release
Imaweb/ IDF Group, a leading independent provider of customer relationship management (“CRM”) solutions and dealership management systems (“DMS”) for the automotive industry in Europe, today announced that it has completed its acquisition of TMS-Soft, a leading provider of digital car registration workflow software in France. Imaweb/ IDF Group is backed by Providence Strategic Growth (“PSG”), the growth equity affiliate of premier asset management firm Providence Equity Partners (“Providence”). Financial terms were not disclosed.
Founded in 2008, TMS-Soft automates and streamlines processes associated with vehicle registration through its cutting-edge, digital platform. The company is the largest of only three non-governmental organizations authorized to issue vehicle registration credentials under the French system, the système d'immatriculation des véhicules (SIV). TMS-Soft’s team serves over 3,700 clients ranging from used car dealerships, auto centers, and online car sales marketplaces.
Patrick Prajs, CEO of Imaweb/ IDF Group, said, “Our acquisition of TMS-Soft will enable us to offer clients a highly valuable add-on to their existing suite of Imaweb/IDF Group products, which are centered around our core CRM and DMS products. We will also be able to reach a broader base of customers – especially used-car dealerships – across all our markets. Today’s announcement is a testament of the momentum we have sustained since partnering with PSG, and we are optimistic about the road ahead. We are pleased to welcome the TMS-Soft team to our family and look forward to working together as we solidify our position as a leading European provider of CRM, DMS, and now digital workflow solutions for the automotive industry in Europe.”
Lionel Amrouche, Founder and CEO of TMS-Soft, said, “This transaction underscores the strength of the TMS-Soft brand and importance of our offering. We are excited for the future and look forward to growing the business under the Imaweb/ IDF Group umbrella.”
Since its formation following PSG’s investment in September 2019, Imaweb/ IDF Group has become one of Europe’s premier full-service providers of automotive CRM, DMS and other digital solutions. In the last 12 months, Imaweb/ IDF Group has also completed the acquisitions of ITMotive, a Netherlands-based distributor and servicer of DMS in the Benelux region, and Serinfer, the computer software segment of the Alvariño Group, a Spanish developer, distributor and supplier of DMS.
Imaweb/ IDF Group
Imaweb/ Datafirst-I’Car Systems Group (“Imaweb/ IDF Group”) is a leading developer of CRM and DMS solutions for the automotive sector in Europe. The company was formed through the merger of Imaweb, a Spanish company dedicated to developing global customer management solutions for sales, marketing and after-sales, and DATAFIRST-I’Car Systems, a French software development company for car manufacturers, groups distribution and dealers, in 2019.
TMS-Soft
TMS-Soft is one of only three non-governmental organizations authorized to issue vehicle registration credentials under the French system, the système d'immatriculation des véhicules (SIV). Through its digital platform, TMS-Soft facilitates all formalities associated with the registration process, with a focus on used vehicle registration. TMS-Soft was founded in 2008 by Lionel Amrouche, who continues to lead the business, and is powered by a team serving over 3,700 clients. Please visit https://www.tms-soft.fr/ for more information.
Providence Strategic Growth
PSG is an affiliate of Providence Equity Partners (“Providence”). Established in 2014, PSG focuses on growth equity investments in lower middle market software and technology-enabled service companies. Providence is a premier global asset management firm that pioneered a sector-focused approach to private equity investing with the vision that a dedicated team of industry experts could build exceptional companies of enduring value. Since the firm’s inception in 1989, Providence has invested in more than 200 companies and is a leading equity investment firm focused on the media, communications, education, software and services industries. PSG is headquartered in Boston, MA, with offices in London and Kansas City. For more information on PSG, please visit https://www.provequity.com/private-equity/psg , and for more information on Providence, please visit https://www.provequity.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200911005129/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TVS Motor Company Returns to EICMA With New Models for Europe26.10.2026 12:45:00 CET | Press release
A year after its Milan debut, TVS Motor returns with a rapidly expanding European footprint and Italian sales up 110%Peyman Kargar to lead TVS Motor’s next phase of global growth as the company expands European footprint TVS Motor Company (TVSM), a global leader in two- and three-wheeler manufacturing, returns to EICMA in Milan this November, one year after its debut at the world’s largest two-wheeler exhibition. The company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET. The TVS stand is in Hall 18, Stand I64. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026990290/en/ TVS Motor Company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET at EICMA this year. EICMA 2025 marked the beginning of TVS Motor's European growth journey. Since then, the company has focused on establishing the foundations for long-term success, building its deal
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 12:00:00 CET | Press release
Improvements in symptoms of pain, stiffness, and range of motion were sustained through two yearsTumor responses remained robust1 and durable2Not intended for U.K.-, U.S.- or Canada-based media Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 11:30:00 CET | Press release
Second limited-edition WHOOP x SR_A collection brings “performance for life” to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments. WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural wo
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 11:28:00 CET | Press release
Oral-B iO helps you avoid new tooth and gum issues—and if you have existing gum problems, it can resolve them quicker than a manual toothbrush. Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom